List of Excipients in Branded Drug VUSION

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Mylan Pharmaceuticals Inc	VUSION	miconazole nitrate, zinc oxide, white petrolatum	0378-8222	BUTYLATED HYDROXYTOLUENE	2028-03-30
Mylan Pharmaceuticals Inc	VUSION	miconazole nitrate, zinc oxide, white petrolatum	0378-8222	TRIHYDROXYSTEARIN	2028-03-30
Mylan Pharmaceuticals Inc	VUSION	miconazole nitrate, zinc oxide, white petrolatum	0378-9730	BUTYLATED HYDROXYTOLUENE	2028-03-30

VUSION Excipient Strategy and Commercial Opportunities in Topical Diaper Dermatitis

Last updated: August 14, 2026

VUSION is a prescription topical ointment containing miconazole nitrate 0.25% and zinc oxide 15% in a petrolatum-based vehicle. Its commercial differentiation depends less on active-ingredient novelty than on excipient control, barrier performance, skin tolerability, manufacturing consistency, pediatric positioning, and prescription-to-OTC or private-label expansion. The principal opportunity is to preserve the product’s antifungal-plus-barrier architecture while improving spreadability, residue, wash-off behavior, packaging, and cost of goods.

What is VUSION and how does its formulation work?

VUSION is indicated for the topical treatment of candidiasis-associated diaper dermatitis. The FDA labeling directs use in pediatric patients, with application to the affected area three times daily for seven days or as directed. It is not intended for children younger than four weeks of age.[1]

What are the active and inactive ingredients in VUSION?

Component	Approximate concentration	Primary formulation role
Miconazole nitrate	0.25%	Antifungal active
Zinc oxide	15%	Skin protectant and physical barrier
White petrolatum	81.35%	Occlusive vehicle and moisture barrier
Mineral oil	3.4%	Emollient, wetting aid, and rheology modifier

The formulation totals approximately 100%. The high petrolatum content creates an occlusive film that limits contact between irritated skin and moisture, urine, and fecal enzymes. Zinc oxide contributes a second barrier function and is widely recognized as a skin-protectant ingredient in topical products.[1,2]

Miconazole nitrate provides antifungal activity against Candida species. The formulation therefore combines pharmacologic treatment with physical protection, a design that distinguishes VUSION from products containing only an antifungal or only a zinc oxide barrier.

How strong is the VUSION excipient strategy?

The excipient strategy is commercially coherent because each major vehicle component supports the product’s use case.

Petrolatum provides occlusion and retention

White petrolatum is the dominant excipient. It has low water content, strong occlusivity, broad dermatologic use, and a long history in pediatric skin-protection products. Its main commercial advantages are low ingredient cost, supply availability, chemical stability, and low sensitization potential compared with many fragrance-containing or preservative-containing vehicles.

Its limitations are equally important:

• High tack and greasy feel
• Difficult removal from skin and clothing
• Potentially poor consumer acceptance during frequent diaper changes
• Risk of inconsistent spread if the wax or hydrocarbon phase is not tightly controlled
• Limited compatibility with some plastic packaging systems

For VUSION, these limitations are partly functional. A persistent film is useful in diaper dermatitis because the product must remain on the skin through exposure to moisture and friction.

Zinc oxide adds a physical barrier claim

Zinc oxide is not merely a filler. At 15%, it materially contributes to the product’s skin-protectant positioning. Particle-size distribution, surface treatment, purity, and dispersion quality can affect opacity, feel, sedimentation, and barrier performance.

A reformulation that changes zinc oxide grade could alter:

• Coverage and whitening
• Film continuity
• Abrasion during application
• Residue after wiping
• Stability of the miconazole dispersion
• Perceived efficacy by caregivers

A lower-cost zinc oxide source may therefore create a larger product risk than its unit-price savings suggest. Pharmaceutical-grade material with controlled heavy-metal limits, particle characteristics, and batch-to-batch consistency is strategically preferable.

Mineral oil controls handling properties

Mineral oil reduces the apparent stiffness of the petrolatum base and improves spreadability. Its concentration is small relative to petrolatum, but it can materially affect:

• Extrusion force
• Skin coverage
• Tube emptying
• Phase homogeneity
• Greasiness
• Low-temperature behavior

A modest change in mineral oil content can produce a different user experience without changing the active ingredients. This creates a practical opportunity for product-line segmentation, such as a standard ointment and a more spreadable “soft barrier” version.

What formulation patents or intellectual-property barriers protect VUSION?

VUSION’s principal product protection is formulation-based rather than biologic or device-based. The relevant technical value lies in the combination of miconazole nitrate, zinc oxide, and a hydrocarbon ointment vehicle for candidiasis-associated diaper dermatitis.

What patent risks apply to a VUSION generic?

A generic applicant would typically evaluate:

1. Composition claims covering the active and excipient combination.
2. Concentration ranges for miconazole nitrate and zinc oxide.
3. Method-of-use claims for candidiasis-associated diaper dermatitis.
4. Physical-property claims involving viscosity, particle dispersion, or film formation.
5. Manufacturing claims covering blending, milling, heating, cooling, or filling.
6. Packaging claims involving tubes, liners, or compatibility with the ointment base.

Because VUSION is a nonsterile topical ointment, the formulation’s physical attributes can be central to FDA approval and product sameness. A competitor may match the labeled ingredients but still face development issues involving spreadability, content uniformity, particle distribution, viscosity, and in vitro release.

Does VUSION have biologic or biosimilar risk?

No. VUSION is a small-molecule topical drug product, not a biologic. Biosimilar pathways under the Public Health Service Act do not apply. Competitive entry would generally arise through an abbreviated new drug application, a 505(b)(2) application, an OTC monograph pathway where legally available, or a reformulated prescription product.

What is the Orange Book status of VUSION?

The FDA Orange Book is the controlling source for current reference-listed-drug, patent, exclusivity, and therapeutic-equivalence information.[3] VUSION’s regulatory position should be evaluated through its NDA record and current Orange Book entries rather than through historical marketing materials.

For commercial planning, the important distinctions are:

Issue	Relevance to VUSION
NDA status	Determines the reference product for abbreviated applications
Listed patents	Can trigger Paragraph IV certification analysis
Pediatric exclusivity	May affect timing if granted
Orphan exclusivity	Not ordinarily expected for diaper dermatitis
Therapeutic equivalence	Depends on FDA-approved topical standards
Patent expiration	Controls litigation and launch timing
Marketing status	Affects whether a generic sponsor can rely on the product

A historical patent expiration date should not be treated as a current market-entry date without checking the latest Orange Book and FDA approval records.

When does VUSION lose exclusivity and what generic entry scenarios exist?

VUSION’s commercial exclusivity is likely to depend more on patent status, product availability, and formulation complexity than on long remaining regulatory exclusivity. A topical product with an older approval may have limited standalone exclusivity but still retain commercial protection through brand recognition, prescribing familiarity, and formulation know-how.

What Paragraph IV challenges could affect VUSION?

A Paragraph IV challenger could assert that listed patents are invalid, unenforceable, or not infringed. The practical risk depends on whether the patents claim:

• The precise miconazole-zinc oxide-petrolatum combination
• Broad concentration ranges
• Specific diaper dermatitis treatment methods
• A narrowly defined manufacturing process
• Measurable physical characteristics that a generic must reproduce

A successful first filer could receive 180-day generic exclusivity under applicable FDA rules. The value of that position would depend on whether other applicants can enter through non-infringing formulations or whether the listed patents remain enforceable.

What generic launch scenarios exist?

Scenario	Likely market effect
No approved generic	Brand retains prescription pricing and channel control
One approved generic	Price erosion may be moderate, with substitution concentrated in Medicaid and managed care
Multiple topical generics	Wholesale price compression and formulary displacement increase
Authorized generic	Brand owner preserves some volume while competing on price
OTC zinc oxide alternatives	Consumer substitution increases without direct miconazole equivalence
New antifungal barrier products	VUSION faces differentiated competition rather than pure generic substitution

Topical generics often compete on acquisition cost, tube size, dispensing convenience, and payer placement. A product that is technically equivalent but harder to spread or remove can lose pediatric prescriber and caregiver preference.

What commercial opportunities exist for VUSION excipients?

The strongest opportunities involve improved usability without changing the therapeutic concept.

Opportunity 1: A less greasy ointment

A lower-tack vehicle could improve caregiver acceptance. The development challenge is to reduce greasiness without weakening the protective film. Potential approaches include:

• Adjusting the petrolatum-to-mineral-oil ratio
• Introducing a compatible low-level wax structure
• Using a more controlled hydrocarbon blend
• Optimizing zinc oxide particle dispersion
• Improving tube delivery and dose control

Any change must preserve content uniformity, antifungal release, stability, and the product’s barrier function.

Opportunity 2: A cream or paste extension

A cream could offer improved washability and cosmetic acceptability. A paste could provide higher zinc oxide loading and stronger barrier persistence. Both approaches create regulatory and technical separation from the original ointment.

A cream would introduce new risks:

• Preservative requirements
• Emulsion instability
• Increased microbial-control burden
• Greater sensitivity to pH and water activity
• Potential change in miconazole solubility and release

A paste may improve barrier performance but worsen spreadability and residue. Each dosage form would need a distinct clinical and consumer value proposition.

Opportunity 3: Preservative-free pediatric positioning

The current hydrocarbon-rich structure is compatible with a preservative-free positioning if water activity remains sufficiently low and manufacturing controls support microbiological quality. This could appeal to caregivers seeking minimal excipient exposure.

The claim must be supported by the actual formulation, container closure, manufacturing process, and stability data. A preservative-free product should not be assumed to be equivalent to the current ointment merely because it uses the same active ingredients.

Opportunity 4: Premium packaging

Packaging is an underused source of differentiation for petrolatum-based products. Opportunities include:

• Smaller tubes for diaper-bag use
• Tamper-evident unit-dose packs
• Low-residue tube interiors
• Controlled-dose nozzles
• Multi-pack hospital and neonatal-care formats
• Packaging that reduces hand contamination

Tube compatibility testing is important because hydrocarbons can interact with some plastics, elastomers, adhesives, and liners. Extractables, leachables, seal integrity, and product weight loss should be assessed under accelerated and long-term conditions.

Opportunity 5: Institutional and private-label supply

Hospitals, pediatric clinics, long-term-care facilities, and retail pharmacy chains may support private-label or contract-manufactured versions. The commercial offer could include:

• Standard prescription-strength ointment
• Institutional tubes with larger fill sizes
• Retail barrier products without miconazole
• A coordinated antifungal and skin-protection line
• Contract development and manufacturing services

A private-label strategy would require careful separation between products containing the drug active and products marketed only as skin protectants. FDA labeling, monograph eligibility, and prescription status would differ.

How does VUSION compare with competing diaper dermatitis products?

Product category	Antifungal activity	Barrier activity	Main vehicle	Commercial position
VUSION	Miconazole	Zinc oxide plus petrolatum	Ointment	Prescription combination
Nystatin products	Nystatin	Usually limited or vehicle-dependent	Ointment or cream	Prescription antifungal
Clotrimazole products	Clotrimazole	Usually limited	Cream	Often OTC antifungal
Zinc oxide products	None	Zinc oxide	Cream, paste, or ointment	OTC skin protectant
Petrolatum products	None	Occlusive barrier	Ointment	OTC low-cost protection
Hydrocortisone products	Anti-inflammatory	Vehicle-dependent	Cream or ointment	Symptom-focused, not antifungal

VUSION’s differentiation is the combination of antifungal treatment and barrier protection in one prescription product. Its main competitive weakness is that caregivers can assemble a lower-cost regimen using an antifungal product and a separate zinc oxide or petrolatum barrier.

The product must therefore justify its premium through convenience, adherence, prescriber confidence, reduced product mixing, and consistent film formation.

What FDA regulatory issues affect VUSION reformulation?

A reformulated VUSION product could require a new strength, new dosage form, supplemental approval, 505(b)(2) application, or an ANDA, depending on the change and the proposed reference product.

Key regulatory comparability tests

A development program should control:

• Assay and impurities for miconazole nitrate
• Zinc oxide identity, assay, and heavy metals
• Content uniformity across the tube
• Particle-size distribution
• Viscosity and yield stress
• Spreadability and extrudability
• In vitro release and permeation
• Microbial limits
• Preservative effectiveness where applicable
• Stability under ICH conditions
• Container-closure compatibility

For topical semisolids, Q3 characterization is commercially important. FDA guidance emphasizes comparative assessment of product attributes such as components, composition, physical structure, and performance.[4]

What manufacturing and supply-chain barriers affect the product?

The basic ingredients are widely available, so raw-material scarcity is unlikely to be the primary barrier. The more important risks are process and quality related.

Manufacturing controls

A robust process should address:

1. Heating and melting behavior of the petrolatum phase.
2. Zinc oxide wetting and deagglomeration.
3. Uniform distribution of miconazole nitrate.
4. Controlled cooling to establish final rheology.
5. Prevention of air incorporation.
6. Filling-temperature control.
7. Tube weight and seal consistency.

Miconazole nitrate and zinc oxide may behave differently during mixing. Inadequate dispersion can produce assay variability, grittiness, or nonuniform drug release even when finished-product assay results appear acceptable.

Excipient sourcing

The commercial formulation should qualify at least two supply sources where possible for:

• White petrolatum
• Mineral oil
• Zinc oxide
• Packaging components

Excipient changes can affect the product’s regulatory comparability. Supplier specifications should cover hydrocarbon profile, oxidation markers, viscosity, microbiological quality, and impurity limits.

What licensing and partnership opportunities exist?

VUSION can support several partnership models:

Partnership model	Target partner	Value proposition
Regional commercialization	Specialty dermatology company	Prescription sales force and payer access
Private label	Retail pharmacy or pediatric brand	Faster channel expansion
Contract manufacturing	Topical pharmaceutical manufacturer	Lower capital requirements
OTC line extension	Consumer-health company	Broader caregiver reach
Hospital supply agreement	Distributor or health system	Institutional volume and formulary placement
Formulation license	Drug-delivery developer	Improved sensory profile or packaging

The most defensible licensing asset would be a validated reformulation with demonstrably improved usability and preserved antifungal performance. A simple excipient substitution is unlikely to command strong licensing economics unless it solves a measurable problem such as tube waste, separation, residue, or caregiver adherence.

What revenue exposure and competitive risks should investors monitor?

VUSION revenue is exposed to four factors:

• Prescription volume for candidiasis-associated diaper dermatitis
• Payer substitution and reimbursement
• Generic or authorized-generic entry
• Consumer substitution with separate antifungal and barrier products

The product’s revenue durability is likely to depend on its ability to maintain a clinical convenience advantage. If payers treat VUSION as interchangeable with lower-cost antifungal products, price pressure will increase. If prescribers value the integrated barrier function, the brand may retain a premium in pediatric dermatology and primary care.

Key indicators include:

• FDA approval of an equivalent topical product
• Orange Book patent or exclusivity changes
• Wholesale acquisition price changes
• Medicaid and commercial formulary placement
• Retail availability of competing miconazole products
• Product complaints involving separation, grittiness, or difficult application
• Changes in pediatric prescribing guidance

Key Takeaways

• VUSION combines miconazole nitrate 0.25% with zinc oxide 15% in a petrolatum-dominant ointment.
• Petrolatum supplies occlusion, zinc oxide supplies barrier protection, and mineral oil improves handling and spreadability.
• The main formulation opportunity is a less greasy, easier-to-remove product that retains film persistence.
• Generic risk is driven by topical formulation sameness, patent status, FDA approval requirements, and payer substitution.
• Biosimilar risk does not apply because VUSION is a small-molecule topical drug.
• Private-label, institutional, packaging, OTC-adjacent, and reformulation opportunities are commercially plausible.
• The strongest defensibility would come from validated performance improvements, manufacturing know-how, packaging compatibility, and regulatory data rather than from commodity excipients alone.

FAQs

Can VUSION be reformulated without changing its regulatory status?

Not automatically. Changes to excipient identity, concentration, dosage form, or product performance may require regulatory review and supporting comparability data.

Is zinc oxide in VUSION responsible for the antifungal effect?

No. Zinc oxide primarily provides skin-protectant and barrier activity. Miconazole nitrate is the antifungal active.

Could a VUSION generic use a cream instead of an ointment?

A cream would generally be a different dosage form and could require a separate regulatory pathway. It would also introduce emulsion stability and preservative-control issues.

Is a preservative-free VUSION formulation commercially attractive?

Yes, particularly for pediatric and caregiver positioning, but the formulation must maintain microbiological quality, stability, and drug uniformity without relying on conventional preservatives.

What is the most important excipient for VUSION performance?

White petrolatum is the dominant excipient by quantity and is central to occlusion and product persistence. Mineral oil and zinc oxide remain important because they affect spreadability, barrier properties, and sensory performance.

References

1. U.S. Food and Drug Administration. (n.d.). Vusion ointment, 0.25% miconazole nitrate and 15% zinc oxide: Prescribing information.
2. U.S. Food and Drug Administration. (2022). OTC monograph M016: Skin protectant drug products for over-the-counter human use.
3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
4. U.S. Food and Drug Administration. (2016). Draft guidance for industry: ANDAs for certain highly purified synthetic peptides and topical dermatological drug products.